Petrovsky National Research Centre of Surgery
Moscow, 119991, Russia
NCT Number: NCT06977646
Hypertrophic cardiomyopathy - is an inherited disease characterized by pronounced genetic and phenotypic heterogeneity. There are two most common anatomic variants of cardiac hypertrophy: subaortic and submitral phenotypes. Subaortic phenotype is characterized by hypertrophy of the basal parts of the heart, mainly in the interventricular septum (IVS), manifesting by a high pressure gradient in the LVOT. Submitral phenotype is characterized by localization of hypertrophic zone downward to the apex and apical phenotype is without a pressure gradient in the LVOT.
The morphology, nature of hemodynamic abnormalities not well studied in patients with apical phenotype of HCM, and surgical treatment are controversial, and for those patients with advanced stage of the HF the orthotopic heart transplantations (HTx) is usually considered.
One of the surgical techniques available for this category of patients is apical myectomy. The main goal of this intervention is increasing the left ventricular volume and improving of the LV compliance with an increase of the diastolic relaxation. Limited data of such procedures in HCM patients were already published but it still requires further investigation on larger cohort of patients.
In this study, the investigators hypothesize that along with left ventricular septal hypertrophy, a small cavity is formed in patients with submittal-apical phenotype due to an increased number of hypertrophied papillary muscles. They are displaced to the apex and tightly fixed both among themselves and to the left ventricular walls. This causes a significant reduction in diastolic volume and left ventricular relaxation capacity. The present study will analyze the experience of performing resection of hypertrophied trabeculae and mobilization of papillary muscles performed through the aorta. Throw this approach procedure can be done without the need for traumatic access and suturing in the apex of the left ventricle.
Interested in participating?
Request Info15 year and older
All sexes
Observational
Moscow, 119991, Russia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The proposed intervention is a variation of classical myectomy, but unlike it, the main substrate for resection is not only the hypertrophied interventricular septum, but the abnormal papillary muscles and interpapillary trabeculae in the left ventricular cavity
Time frame: Assessment by medical records during the first 28 days after surgical intervention
Binary value: of alive/dead
Time frame: Perioperative/Periprocedural
Diastolic left ventricular function relying on echo protocols. E/A ratio as an equation of an early transmitral flow (E wave) and a late flow with atrial contraction (A wave). An E/A ratio less than 0.75 or greater than 1.5 indicates dyastolic disfunction.
Time frame: 1 month after surgery
Functional class of heart failure according to New York Heart Association (NYHA) Functional Classification of heart failure
Time frame: Perioperative/Periprocedural
Binary value: yes/no
Time frame: hrough study completion, an average of 1 year
Binary value yes/no According to available medical records for the entire follow-up period
Time frame: through study completion, an average of 1 year
Pathogenicity assessment of candidate genetic variants is performed according to the ACMG recommendations (2015) Will be performed on patients who have a preserved tissue sample suitable for whole genome sequencing
Petrovsky National Research Centre of Surgery
Other
Retrospective Study of the Surgical Treatment Restrictive Form of the Hypertrophic Cardiomyopathy Without of the Left Ventricular Outflow Tract Obstruction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05100420
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Edmonton, Alberta, Canada
View Trial DetailsNCT04189822
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Vancouver, British Columbia, Canada
View Trial DetailsNCT06546137
Abnormalities, Multiple, Aneurysm
Rio Branco, Acre, Brazil
View Trial DetailsNCT07372196
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Novosibirsk, Novosibirsk Oblast, Russia
View Trial Details